Mutational study of p16CDKN2/MTS1/INK4A and p57KIP2 genes in hepatocellular carcinoma

International Journal of Oncology

Volumn 12, Issue 3, 1998, Pages 583-588

  Bonilla, Felix ^a,b   Orlow, Irene ^a   Cordón Cardó, Carlos ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Molecular Diagnostic Unit   (Spain)

Author keywords

Deletions; Hepatocellular carcinoma; Microsatellite alterations; p16; p57

Indexed keywords

CDKN1C PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1C; ENZYME INHIBITOR; MICROSATELLITE DNA; NUCLEAR PROTEIN; PROTEIN P16INK4A; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE INHIBITOR; DNA; DNA MARKER; PROTEIN P16;

AMINO ACID SUBSTITUTION; ARTICLE; GENETICS; HUMAN; LIVER; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; NUCLEOTIDE SEQUENCE; POINT MUTATION; POLYMERASE CHAIN REACTION; REFERENCE VALUE; SINGLE STRAND CONFORMATION POLYMORPHISM; SOUTHERN BLOTTING; CHROMOSOME 9P; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; GENE MUTATION; HUMAN TISSUE; PRIORITY JOURNAL;

AMINO ACID SUBSTITUTION; BASE SEQUENCE; BLOTTING, SOUTHERN; CARCINOMA, HEPATOCELLULAR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P57; ENZYME INHIBITORS; HUMANS; LIVER; LIVER NEOPLASMS; MICROSATELLITE REPEATS; NUCLEAR PROTEINS; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; REFERENCE VALUES;

EID: 0031594325     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.3.583     Document Type: Article

References (34)

1. Clurman BE and Roberts JM: Cell cycle and cancer. J Natl Cancer Inst 87: 1499-1501, 1995.
2. Kamb A, Gruis AG, Weaver-Feldhaus J, Lui Q, Harsman K, Tavtigan SV, Stokert D, Day RS, Johnson BE and Skolnick MH: A cell regulator potentially involved in genesis of many tumor types. Science 264: 436-440, 1994.
3. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K and Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756, 1994.
4. Serrano M, Hanon GJ and Beach DB: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707, 1993.
5. INK4 Cancer Res 54: 5816-5820, 1994.
6. Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N and Markowitz S: Deletions of p16 CDKN2/MTS1/INK4 and p15 genes in brain tumors. Cancer Res 54: 6353-6358, 1994.
7. Washimi O, Nagatake M, Osada H, Ueda R, Koshikawa T and Seki T: In vivo ocurrence of p16 CDKN2/MTS1/INK4(MST1) and p15(MST2) alterations preferentially in non-small cell lung cancer. Cancer Res 55: 514-517, 1995.
8. Mori T, Miura K, Aok T, Mori S and Nakamura Y: Frequent somatic mutations of the MTS1/CDK41 (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 54: 3396-3397, 1994.
9. Cairns P, Mao L, Merlo A, Lee D, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund J and Sidransky D: Rates of pi6 CDKN2/MTS1/INK4(MTS1) mutations in primary tumors with 9p loop. Science 265: 415-416, 1994.
10. Spruck C, Gonzalez-Zulueta M, Shibata A, Simoneau A, Lin M, Gonzales F, Tsai Y and Jones P: P16 CDKN2/MTS1/INK4 gene in uncultured tumors. Nature 370: 183-184, 1994.
11. Orlow I, Lacombe L, Hannon GH, Serrano M, Pellicer I, Dalbagni G, Reuter VE, Zhang ZF, Beach D and Córdon-Cardó C: Deletion of p16 CDKN2/MTS1/INK4 and p15 genes in human bladder tumors. J Natl Cancer Inst 87: 1524-1529, 1995.
12. Hussussian ChJ, Struewing JP, Goldstein AM, Higgins PAT, Ally DS, Shehan MD, Clark H, Tucker MA and Dracopoli NC: Germline p16 CDKN2/MTS1/INK4 mutations in familial melanoma. Nat Genet 3: 15-21, 1994.
13. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G and Kamb A: Complex structure and regulation of the p16 (Mts1) locus. Cancer Res 55: 2988-2994, 1995.
14. Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ and Sidransky D: A novel p16 INK4 transcript. Cancer Res 55: 2995-2997, 1995.
15. KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 9: 639-649, 1995.
16. CIP1 Cdk inhibitory family, is a candidate tumor suppressor gene. Genes Dev 9: 650-662, 1995.
17. Okuda K: Hepatocellular carcinoma: recent progress. Hepatology 15: 948-963, 1992.
18. Dalbagni G, Presti J, Reuter V, Fair WR and Córdon-Cardó C: Genetic alterations in bladder cancer..Lancet 342: 469-471, 1993.
19. Orita M, Suzuki Y, SekiyaT and Hayashi K: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5: 874-879, 1989.
20. Fujimori M, Tokino T, Hino O, Kitagawa T, Imamura T, Okamoto E, Mitsunobu M, Ishikaba T, Nakagama H, Harada H, Yagura M, Matsubara K and Nakamura Y: Allelotype study of primary hepatocellular carcinoma. Cancer Res 51: 89-93, 1991.
21. Tsuda H, Zhang W, Shimasoto Y, Yokota J, Terada M, Sugimura T, Miyamura T and Hirohashi S: Allelic loss on chromosome 16 associated with progression of human hepatocellular carcinoma. Proc Natl Acad Sci USA 87: 6791-6794, 1990.
22. Buetow KH, Murray JC, Israel JL, London WT, Smith M, Kew M, Blanquet V, Brechot C, Redeker A and Govindarajah S: Loss of heterozygosity suggests tumor suppressor gene responsible for primary hepatocellular carcinoma. Proc Natl Acad Sci USA 86: 8852-8856, 1989.
23. Rogler CE, Sherman M, Su CY, Shafritz DA, Summers J, Shows TB, Henderson A and Kew M: Deletion in chromosoma lip associated with a hepatitis B integration site in hepato-cellular carcinoma. Science 230: 319-322, 1985.
24. Puisieux A, Galvin K, Troalen F, Bressac B, Marcais Ch, Galun E, Ponchel F, Yakicier C, Ji J and Ozturk M: Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. FASEB J 7: 1407-1413, 1993.
25. Ponchel F, Puisieux A, Tabone E, Michot JP, Froschl G, Morel AP, Frebourg T, Fontaniere B, Oberhammer F and Ozturk M: Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor B1-mediated apoptosis. Cancer Res 54: 2064-2068, 1994.
26. Nagai H, Ponglikitmongkol M, Mita E, Ohmachi Y, Yoshikawa H, Saeki R, Yumoto Y, Nakanishi T and Matsubara K: Aberration of genomic DNA in association with human hepatocellular carcinomas detected by 2-dimensional gel analysis. Cancer Res 54: 1545-1550, 1994.
27. Zhang S-Y, Klein-Szanto AJP, Sauter ER, Shafarenko M, Mitsunaga S and Nobori T: Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 54: 5050-5053, 1994.
28. Nawroz H, Koch W, Anker P, Stroun M and Sidransky D: Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med 2: 1035-1037, 1996.
29. Orlow I, Lianes P, Lacombe L, Dalbagni G, Reuter VE and Cordón-Cardó C: Chromosome 9 allelic losses, and microsatellite alterations in human bladder tumors. Cancer Res 54: 2848-2851, 1994.
30. KIP2: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 55: 1211-1214, 1995.
31. Orlow I, Iavarone A, Crider-Miller SJ, Bonilla F, Latres E, Lee M-H, Gerald WL, Massagué J, Weissman BE, and Cordón-Cardó C: Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue sarcomas and Wilms' tumors. Cancer Res 56: 1219-1221, 1996.
32. KIP2, a cyclin-dependent kinase inhibitor, in mouse. Nat Genet 11: 204-206, 1995.
33. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JPJ, Davidson NE, Sidransky D and Baylin SB: Inactivation of the CDKN2/p16/ MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525-4530, 1995.
34. Gonzalez-Zulueta M, Bender ChM, Yang AS, Nguyen T, Beart RW, van Tornout JM and Jones PA: Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55: 4531-4535, 1995.